Navigation Links
Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
Date:1/28/2009

Product is Japan's first second-generation drug-eluting stent

NATICK, Mass., Jan. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the product as soon as reimbursement approval is granted, which is expected in the coming weeks.

TAXUS Liberte is the only second-generation drug-eluting stent approved for use in Japan. Design improvements over the Company's first-generation TAXUS(R) Express2(TM) Stent include thinner struts to allow better stent deliverability and conformability, as well as a more uniform stent geometry for consistent lesion coverage and drug distribution.

"The TAXUS Liberte Stent is the latest advance in drug-eluting stent technology for Japan," said Donald Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "Its safety and efficacy have been well demonstrated in multiple clinical studies and years of clinical use."

"We are very pleased with this approval, which provides access to proven technology to Japanese physicians and their patients," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We are committed to continuing to provide the most innovative products and therapies to the Japanese market."

The TAXUS Liberte Stent uses proven paclitaxel-eluting technology, which has been evaluated by the industry's most extensive randomized, controlled clinical trial program, and studied in 35,000 real-world patients enrolled in post-approval registries. More than 4.6 million TAXUS Stent Systems have been implanted globally.

The TAXUS Liberte Stent will replace the TAXUS Express2
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
2. Boston Scientific Acquires Labcoat Limited
3. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
4. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
5. Boston Scientific to Participate in Piper Jaffray Health Care Conference
6. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
7. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
8. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
9. InterMune to Present at Deutsche Bank Biotech Boston Confab
10. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
11. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),...ounced today that it executed,a joint venture (JV)...echnology Co., Ltd. (Sinovac Dalian). The JV will ...-use vaccines. Sinovac will contribute its experti...g world-class vaccines; the,other party will bring...
(Date:11/25/2009)...wire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq...rm.D., president and chief executive officer, will...are Conference. , ,Presentation details are as fo...erence,Date: Tuesday, December 1, 2009,Time: ...k Palace Hotel, New York, NY,Webcast: <a href=,...
(Date:11/24/2009)...swire-FirstCall/ -- IES (Nasdaq: IESC ), a leadin...ns systems and services for the commercial, indust... its commercial business group has been awarded a ...lectrical systems for the Level 4 bio-safety lab (...al Research Institute of Infectious Diseases (USAM...
(Date:11/24/2009)...investment bank KTA Capital,s client Neuren Pharma...onvertible note private placement with a U.S. inst...nged by KTA Capital as Neuren,s exclusive placemen...w York (PRWEB) November 23, 2009 -- The independen...;KTA Capital") has announced that its client ...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
... ExonHit Therapeutics, a,drug and diagnostic disco...st blood-based Alzheimer,s disease test. The compa...ide it as a service in its GLP (Good,Laboratory Pr...cal industry,as early as 2009. This initial ExonH...lzheimer,s disease from a simple blood sample. Fur...
...Are Among The Organizations Advocating Use of Hand...and Protection, NORCROSS, Ga., Nov. 8 Headlines ...ureus) deadlier than AIDS, and the media continue,...the most extreme cases,student deaths due to this ...washing is advocated as one of the best means of p...
... Nov. 8 Ortho Biotech,Products, L.P. today modifi... alfa), following guidance from the U.S. Food and ...ll drugs within the,erythropoiesis-stimulating age...e based on previously reported data,and include re...s Advisory,Committee meeting, and the September 11...
Other Biology Technology:ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4Soap and Water May not be Enough to Fight MRSA Superbug 2Soap and Water May not be Enough to Fight MRSA Superbug 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 5
(Date:11/30/2009)...ajor obstacle to HIV research is the virus,s exqui...at scientists, traditional tools, like the humble ...ow, a team of researchers writing in BioMed Centra...ingenious assault on this problem by creating a mo... being infected with HIV. , George Kassiotis, fr...
(Date:11/30/2009)... , VILNIUS, Lithuania, Nov. 30 /PRNewsw...gy.com ), a provider of high-precision biometric i...pgrades in the company,s core product line: VeriL... recognition and MegaMatcher 3.1 SDK for large-s...ntification systems (AFIS). Expanded capabilities ...
(Date:11/26/2009)...zed for their impressive antlers, red deer have be...But a deer,s antlers are much more than decorative...r when duelling. John Currey, from The University ...properties of bone for over half a century and has... antler through a long-standing collaboration with...
Breaking Biology News(10 mins):A reductionist approach to HIV research 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Tough yet stiff deer antler is materials scientist's dream 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3Extra care for outwardly healthy workers costs companies millions annually 59951 1Extra care for outwardly healthy workers costs companies millions annually 59951 2Nanowire biocompatibility in the brain 3A So far so good 10481 1Nanowire biocompatibility in the brain 3A So far so good 10481 2
...Lotions and potions that promise to remove wrinkle... shelves, but do these treatments really work? , V...have identified new molecular indicators -- or "bi...ed to evaluate anti-aging therapies. Their finding...l of Investigative Dermatology. , "There,s a lot ...
...Attaching a recently discovered cytokine to neural...at Cedars-Sinai Medical Center,s Maxine Dunitz Neu...k and kill malignant brain tumor cells and provide...lts of an animal study are published in the March ...ers are now applying to regulatory agencies to tra...
...A new study on identifying which patients were lik... liver transplant (LDLT) found that measuring how ...r shortly after surgery was an accurate indicator ...tor of the outcome of the procedure. The study use... making it particularly useful in treating transpl...
Other Biology News:Biomarkers may hone anti-aging therapies 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3Predicting successful outcomes in living-donor liver transplants 2Predicting successful outcomes in living-donor liver transplants 3
...ot automates LC micro-fractionation, spotting and ...tem, LC eluent can be accurately and continuously ... allows for automatic preparation of target plates...nction with Shimadzus Two-Dimensional Micro LC Sys...
...-Jun NH2-terminal kinase) signal transduction casc... in mammals. JNK pathway activation occurs in resp...he nuclear accumulation of JNK itself, and is impl...ion, oncogenic transformation, morphogenesis, and ...
HP GenomeWide siRNA from QIAGEN
...Screen cDNA Library Panels were designed for full-... PCRs to identify the desired cDNA clone. The firs...late," where each well contains plasmid DNA from 5...) by gel electrophoresis of the reaction products,...
Biology Products: